Go Deep
Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,630 | 6.2 | 0.50 | 0.60 | 189.72 |
| Oct 2026 | 21,630 | 6.2 | 0.50 | 0.60 | 189.93 |
| Oct 2026 | 21,714 | 6.2 | 0.49 | 0.60 | 185.70 |
| Oct 2026 | 21,642 | 6.1 | 0.50 | 0.60 | 188.85 |
| Oct 2026 | 21,707 | 6.2 | 0.49 | 0.60 | 185.27 |
Sinopharm Group Co. Ltd. Quarterly Results
Quarterly data isn't available for this company right now.
Sinopharm Group Co. Ltd. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 575,167,877,000.0 | 584,507,930,000.0 | 596,569,565,000.0 | 552,147,550,000.0 | — |
| Net Profit | 7,155,094,000.0 | 7,049,683,000.0 | 9,053,760,000.0 | 8,525,655,000.0 | — |
| EPS | 2.3 | 2.3 | 2.9 | 2.7 | — |
Sinopharm Group Co. Ltd. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 390,361,212,000.0 | 392,831,244,000.0 | 383,394,844,000.0 | 364,775,134,000.0 | — |
| Total Liabilities | 256,201,470,000.0 | 266,143,942,000.0 | 263,076,099,000.0 | 254,705,944,000.0 | — |
| Total Equity | 83,953,384,000.0 | 78,883,795,000.0 | 74,582,217,000.0 | 68,068,559,000.0 | — |
Owes vs Owns
Sinopharm Group Co. Ltd. owed ¥0.66 for every ¥1 it owned in Dec 2025, down from ¥0.70 in Dec 2022.
| Period | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.66× | 0.68× | 0.69× | 0.70× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sinopharm Group Co. Ltd. Assets & Liabilities Breakdown (CNY millions)
What it owns — Dec 2025
Cash & short-term investments 12.5%Receivables 49.9%Inventory 16.2%Fixed assets (tangible) 4.2%Intangible assets 2.6%Long-term investments 2.7%Other assets 11.9%
How it's funded — Dec 2025
Short-term debt 16.2%Long-term debt 0.9%Payables 39.6%Other liabilities 8.8%Shareholders' equity 34.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 48,796.3 | 54,313.5 | 63,809.1 | 55,222.1 |
| Receivables | 194,613.0 | 187,635.4 | 169,002.9 | 155,578.6 |
| Inventory | 63,341.3 | 62,352.8 | 60,027.6 | 60,925.8 |
| Fixed assets (tangible) | 16,255.7 | 17,612.1 | 18,049.7 | 17,792.4 |
| Intangible assets | 10,147.8 | 10,969.2 | 12,044.1 | 12,025.7 |
| Long-term investments | 10,612.3 | 10,167.9 | 9,710.8 | 8,987.7 |
| Other assets | 46,594.8 | 49,780.3 | 50,750.6 | 54,242.9 |
| Liabilities & equity | ||||
| Short-term debt | 63,321.2 | 62,729.0 | 54,730.4 | 52,997.2 |
| Long-term debt | 3,645.5 | 8,637.2 | 13,834.0 | 11,750.4 |
| Payables | 154,750.1 | 156,869.7 | 154,747.4 | 144,616.7 |
| Other liabilities | 34,484.7 | 37,907.9 | 39,764.2 | 45,341.6 |
| Shareholders' equity | 134,159.7 | 126,687.3 | 120,318.7 | 110,069.2 |
| Net tangible assets | 73,805.6 | 67,914.5 | 62,538.1 | 56,042.8 |
Sinopharm Group Co. Ltd. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 14,138,206,000.0 | 11,546,015,000.0 | 17,173,030,000.0 | 20,963,787,000.0 | — |
| Investing Activities | -963,888,000.0 | -3,750,925,000.0 | -944,535,000.0 | -3,589,622,000.0 | — |
| Financing Activities | -18,686,646,000.0 | -17,285,034,000.0 | -7,643,970,000.0 | -5,693,481,000.0 | — |